FZD1

Across TCGA pan-cancer cohorts, FZD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FZD1 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FZD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FZD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where FZD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	35	view →
LSCC	DFS	Quartile	All	0.193	0.890	.006	11	view →
LUAD	OS	Median	II,III,IV	1.000	0.807	.010	9	view →
UCEC	DFS	Tertile	III,IV	0.355	1.000	.022	8	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FZD1–PDAC (DFS)

Open the PDAC breakdown →